SCHEMBL2107016

SCHEMBL2107016

CC(C)(O)CCCCc1cccc(OCc2ccc(CO)c(CO)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
VDR P11473 3/20 0.48
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MGLL Q99685 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
PPARG P37231 2/20 0.39
PPARA Q07869 2/20 0.39
FFAR1 O14842 1/20 0.39
MAOB P27338 3/20 0.38
ABCB1 P08183 1/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
BCHE P06276 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6886823 0.88 VDR (0.45) VDRCYP4F2CYP4A11NOS1NOS2
SCHEMBL6155482 0.86 BCHE (0.49) VDRSMN1; SMN2BCHE
SCHEMBL6155828 0.84 BCHE (0.50) VDRSMN1; SMN2BCHE
SCHEMBL6158470 0.83 NOS1 (0.38) VDRCYP4F2CYP4A11MGLLNOS1
SCHEMBL6155485 0.81 VDR (0.45) VDRNOS1NOS2
SCHEMBL15556080 0.81 VDR (0.45) VDRCYP4F2CYP4A11TSHRSMN1; SMN2
SCHEMBL6155571 0.81 VDR (0.46) VDRFFAR1BCHE
SCHEMBL6155242 0.81 VDR (0.44) VDRFFAR1BCHE
SCHEMBL6884483 0.81 VDR (0.48) VDRCYP4F2CYP4A11TSHRSMN1; SMN2
SCHEMBL2107635 0.81 MGLL (0.46) CYP4F2CYP4A11MGLLPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP claimed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US claimed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP claimed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO claimed
EP-2879656-B2 DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE OREAL (FR) 2024-07-17 EP disclosed
US-11730682-B2 Self-standing cosmetic sheet L'OREAL (FR) 2023-08-22 US disclosed
EP-2879649-B2 DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT OREAL (FR) 2022-08-24 EP disclosed
EP-2836187-B1 SELF-STANDING COSMETIC SHEET OREAL (FR) 2021-12-08 EP disclosed
CN-112472619-A Dye composition, dyeing method and suitable device 莱雅公司 2021-03-12 CN disclosed
EP-2879656-B1 DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE OREAL (FR) 2019-05-29 EP disclosed
US-10226411-B2 Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device L'OREAL (FR) 2019-03-12 US disclosed
US-10201483-B2 Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device L'OREAL (FR) 2019-02-12 US disclosed
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof L'OREAL (FR) 2005-08-04 US disclosed
EP-1559398-A1 Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins L'OREAL (FR) 2005-08-03 EP disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 US disclosed
EP-1262168-A1 Composition containing fibres to combat the skin aging process L'OREAL (FR) 2002-12-04 EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10226411-B2 Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device KRT18, OAT, DSG1 VDR 3553/4885CYP4F2 2209/4885CYP4A11 2333/4885
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 VDR 4/4885CYP4F2 60/4885CYP4A11 123/4885
US-10201483-B2 Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device KRT18, CUTA, DSG1 VDR 3276/4885CYP4F2 1560/4885CYP4A11 1105/4885
US-11730682-B2 Self-standing cosmetic sheet CUTA, DSG1, SUCLG1 VDR 4085/4885CYP4F2 4281/4885CYP4A11 4206/4885
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof KRT18, PROC, CUTA VDR 514/4885CYP4F2 1050/4885CYP4A11 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.